The UK’s Advanced Research and Invention Agency (ARIA) is making a notable commitment to groundbreaking science by dedicating £66 million to 19 research initiatives aimed at making the mitochondrial genome programmable. Mitochondria, often referred to as the powerhouse of the cell, are critical for providing energy for cellular activities. While there has been progress in genetic engineering that permits the manipulation of nuclear DNA, similar strides for mitochondrial DNA have not kept pace.
ARIA’s new Precision Mitochondria program will promote research in the UK, Germany, the US, and Australia. The goal of the program is to achieve consistent and reproducible expression of innovative genes from engineered mitochondrial DNA within an in vivo setting. This achievement could revolutionize mitochondria from simple targets into programmable entities, potentially facilitating therapies that re-program mitochondria to fight disease and improve cellular operations.
Ryan Olf, the program’s director, emphasized the role of mitochondria in regulating metabolism, immune signaling, and cell death – all of which are factors in numerous age-related diseases such as type 2 diabetes, Alzheimer’s, and cancer. Nevertheless, mitochondria possess their own DNA, which remains challenging to modify. Gaining insights into alterations in mitochondrial DNA that lead to or follow disease, or that might be counteracted, could pave the way for programmability, potentially enabling cellular mechanisms to internally sense and combat disease.
Hansong Ma, a mitochondrial geneticist at the University of Birmingham and leader of one of the supported projects, views this as an exhilarating initiative that goes beyond merely treating diseases. It encompasses the development of technology to govern a fundamental component of life, unlocking new pathways for scientific progress.